These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16933299)

  • 1. fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection.
    Rocca MA; Agosta F; Colombo B; Mezzapesa DM; Falini A; Comi G; Filippi M
    Hum Brain Mapp; 2007 May; 28(5):373-82. PubMed ID: 16933299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
    Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
    J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
    Kita M; Goodkin DE; Bacchetti P; Waubant E; Nelson SJ; Majumdar S
    Neurology; 2000 May; 54(9):1741-5. PubMed ID: 10802778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
    Clanet M; Kappos L; Hartung HP; Hohlfeld R;
    Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study.
    Fernández O; Arbizu T; Izquierdo G; Martínez-Yélamos A; Gata JM; Luque G; de Ramón E
    Acta Neurol Scand; 2003 Jan; 107(1):7-11. PubMed ID: 12542507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
    Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
    Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
    Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
    Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
    Simon JH; Lull J; Jacobs LD; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Sheeder J; Miller D; McCabe K; Serra A; Campion MK; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE
    Neurology; 2000 Jul; 55(2):185-92. PubMed ID: 10908888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
    Clanet M; Radue EW; Kappos L; Hartung HP; Hohlfeld R; Sandberg-Wollheim M; Kooijmans-Coutinho MF; Tsao EC; Sandrock AW;
    Neurology; 2002 Nov; 59(10):1507-17. PubMed ID: 12451189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
    Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
    Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.
    Leuschen MP; Filipi M; Healey K
    Mult Scler; 2004 Dec; 10(6):636-42. PubMed ID: 15584488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.